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The bibliometric characteristics of systematic reviews (SRs) in dermatology are unknown. We analyzed a
group of 309 SRs using Scopus and the ISI Web of Science. These 309 SRs were published between 2008
and 2012 in journals with a median journal impact factor of 3.63; 48.2% (n ¼ 149) included meta-
analysis, 11.6% (n ¼ 36) were Cochrane reviews, and 76.7% (n ¼ 237) summarized enough evidence to
inform clinical decisions. The most common country of origin was the USA (n ¼ 66, 21.4%), and the most
frequently studied disease was psoriasis (n ¼ 50, 16.2%).
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Systematic reviews (SRs) are a type of research aimed at identifying
and synthesizing literature relevant to a speciﬁc research question
and are considered the highest level of evidence. There are many
different sources of SRs, one of which is the Cochrane Collaboration
(CC), the most methodologically rigorous source and reservoir of
SRs.1
Bibliometrics is a type of research based on the quantitative
analysis of publications as away of understanding the development
of a ﬁeld of knowledge as a whole. Bibliometric studies can be used
to study the regional patterns of research, as well as to deﬁne the
content, citations, and funding sources in speciﬁc areas of medical
research.2
There are two databases widely used to obtain and analyze ci-
tations and other bibliometrics: Web of Science (WOS) and Scopus
(SC). WOS was the only way to obtain citation counts until 2004,
which was the time when SC became available. Both databases
require a paid subscription and provide broad coverage of selected
peer-reviewed journals, including CC-SRs.2WhereasWOS hasmorey have no ﬁnancial or non-
atter or materials discussed
logy, Pontiﬁcia Universidad
cal Association. Published by Elsevrestricted criteria for journal inclusion, SC provides full coverage to
all Medline indexed journals.
The number of dermatologic SRs is increasing at a steady rate;
however, there are no studies of bibliometrics in dermatologic SRs,
with only scarce descriptive analyses in other health specialties.3,4
Consequently, information such as the type and the journal impact
factor (JIF), where dermatologic SRs are published, the number of
citations, the main research questions, the country of origin of re-
viewers, the role of CC, the funding sources, among other features,
are absolutely unknown.
We developed a cross-sectional bibliometric study with the
objective of characterizing the main bibliometric features of a
group of SRs in dermatology.Methods
We searched for dermatologic SRs and citations to them in SC and
WOS in December 2013. We decided to analyze both databases
because they have differences in coverage, accessibility, and
updating, and because they have differences in the retrieved
number of citations.2 The search was restricted to SRs published
from January 2008 to December 2012, because it allowed for a
minimum of 1 year to accumulate citations for the most recently
published SRs. Searches were restricted to records with the words
“meta-analysis” or “systematic review” in the title, considering that
the Preferred Reporting Items for Systematic Reviews and Meta-ier Taiwan LLC. All rights reserved.
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term in the title.5 We did not use a language restriction. Search
strategies are available in Table 1. As CC-SRs are not labeled as
“meta-analysis” or “systematic review” in the title, we performed a
separate search of the Cochrane Skin Group (CSG) database in order
to ﬁnd SRs ﬁrst published in the same time span. The bibliometrics
of CSG-SRs were obtained from WOS and SC.
The records and full texts obtained from the three searches
(n ¼ 801) were gathered for analysis. For inclusion, the review had
to fulﬁll the Database of Abstracts of Reviews of Effectiveness
criteria for SRs.6 Article inclusion and data extraction were per-
formed independently by two reviewers, and disagreements were
resolved through discussion. The variables collected for each SR and
the journal where each SR was published are summarized in
Table 1. An SR was catalogued as clinically useful when data pro-
vided at least sufﬁcient evidence to allow reviewers to support
recommendations or suggestions. If the authors did not present any
clinical recommendation based on SR data, this review was cata-
logued as clinically useless.
All statistical tests were two-tailed with the signiﬁcance level
set at 0.05. Categorical variables were tested using the Chi-square
test. Because all numerical variables were nonnormally distrib-
uted, analysis was performed using the KruskaleWallis test.
Results
After excluding duplicates, we obtained a ﬁnal number of 309
assessed SRs. The vast majority (95.8%) were published in WOS
indexed-journals (median 2-year JIF, 3.63; range, 0.228e29.978);
WOS citations per year available to be cited ranged between 0 andTable 1 Search strategies used for WOS and Scopus databases, and variables
collected for each SR and journal where each SR was published.
Search strategies
Scopus
#1 Title ¼ [(systemat * and review *) or (meta-anal *) or (metaanal *) or
(metanal *)]
#2 Afﬁliation¼ (derm * or skin * or cutan *)
#1 and #2
Web of Science
#1 Title ¼ [(systemat * and review *) or (meta-anal *) or (metaanal*) or
(metanal *)]
#2 Research area ¼ dermatology
#3 WOS category ¼ dermatology
#4 Address¼ (derm* OR skin* OR cutan*)
#1 and (#2 or #3 or #4)
Analyzed variables for each systematic review
 Number and countries for all the authors and the corresponding author
 Funding a
 Type of intervention and studied skin disease
 Presence of meta-analysis
 Mean number of cites b
 Clinical usefulness c
 If the analyzed SR was based on randomized controlled trials
 Presence of cooperation d
Variables for each journal
 Two-year JIF e
 If the journal was primarily dedicated to dermatology f
JIF ¼ journal impact factor; SR ¼ systematic review; WOS¼Web of Science.
a If reported or not, and the origin of funding if reported.
b Cites per year available to be cited in Web of Science at December 2013,
calculated as 2013 minus year of publication.
c An SR was catalogued as clinically useful when data provided at least sufﬁcient
evidence to allow reviewers to support recommendations or suggestions. If authors
did not present any clinical recommendation based on SR data, this review was
catalogued as clinically useless.
d Deﬁned as at least one coauthor from a different country than the corresponding
author's country.
e Journal Citation Reports Science Edition 2012.
f Cochrane Library was considered a nondermatological journal.46 citations (median ¼ 3.5); and only 12 SRs (3.9%) were published
in languages other than English. Distribution of citations was
asymmetrical: 10% of the most cited SRs had 39% of the total cita-
tions, and 10% of the least cited SRs had 0.1% of the total citations.
None of the CSG-SRs were among the 10% most cited reviews, nor
were the number of citations or the 2-year JIF of a journal different
along the analyzed years (p ¼ 0.118 and 0.274, respectively).
A total of 36 SRs (11.6%) corresponded to CSG-SRs, and 165 SRs
(53.4%) were published in dermatology specialty journals. In 149
SRs (48.2%) a meta-analysis was conducted, and 35.3% (n ¼ 109)
were SRs based exclusively in randomized controlled trials. A total
of 237 SRs (76.7%) summarized enough evidence to inform clinical
decision making. We did not ﬁnd any differences in the proportion
of these categories in the analyzed years (p ¼ 0.190, 0.354, 0.445,
0.709, and 0.653, respectively).
The most common country of origin of the corresponding
author was the USA (n¼ 66, 21.4%), followed by China (n¼ 37, 12%),
the United Kingdom (n ¼ 34, 11%), and the Netherlands (n ¼ 31;
10%). International collaboration was present in 27.8% (n ¼ 86) of
SRs. The most frequently studied diseases were psoriasis (n ¼ 50;
16.2%), followed by skin infections (n ¼ 35; 11.3%), nonmelanoma
skin cancer (n ¼ 29; 9.4%), atopic dermatitis (n ¼ 29; 9.4%), adverse
drug reactions (n ¼ 25; 8%), melanoma (n ¼ 24; 7.7%), and wounds
(n ¼ 21; 6.7%). Meanwhile, the most frequently studied in-
terventions were medications (n ¼ 131; 42.4%), followed by
epidemiological studies (n ¼ 48; 15.5%). A list of the diseases and
interventions least analyzed (i.e., <10 SRs in the whole study
period) is shown in Table 2.
We did not ﬁnd any differences in the percentage of the most
frequently recorded corresponding author countries, international
collaboration, the most frequently studied diseases, or the most
frequently analyzed interventions, along all the years analyzed
(p ¼ 0.190, 0.319, 0.554, and 0.222, respectively).
Finally, a total of 46 SRs (14.9%) did not report if the authors
received funding, and 130 (42%) were funded SRs. In the case of
funded SRs, the funding sources came from government (n ¼ 34;
26.1%), mixed (private foundations and universities) (n ¼ 34;
26.1%), industry (n ¼ 32; 24.6%), and private foundations (n ¼ 30;
23.1%). Evolution of different categories of funding during the 4
years was as follows: in 2008, funded SRs were more frequent than
nonfunded ones (p ¼ 0.020). Industry funding was the least rep-
resented funding source in 2009 (p ¼ 0.048), and the mostTable 2 Diseases (or conditions) and interventions less analyzed (i.e., <10 SR in the
entire 4-year study period).
Diseases Number
of SRs found
% from the total
of SRs found
Seborreic dermatitis 2 0.65
Skin manifestations of systemic disorders 2 0.65
Urticaria 2 0.65
Contact dermatitis 4 1.29
Vascular malformations 4 1.29
Papulo-escamous disorders other than psoriasis 5 1.62
Immunobullous diseases 5 1.62
Vitiligo 6 1.94
Aesthetical conditions 7 2.27
Noninfectious diseases of nail and hair 8 2.59
Educational interventions and teledermatology 8 2.59
Acne and rosacea 9 2.91
Burns 9 2.91
Interventions
Immunizations 3 0.97
Nutritional modiﬁcations 4 1.29
Skin surgery 6 1.94
Psychological 6 1.94
Complimentary medicine 7 2.27
SR ¼ systematic review.
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were no differences in the sources of funding and between funded
and nonfunded SRs.Discussion
According to our ﬁndings, dermatologic SRs are characterized as
being massively published in WOS indexed and English language
journals, with approximately one half being published in derma-
tology specialty journals with an average JIF for dermatology spe-
cialty, but considered low for general health literature.7
Importantly, >75% of SRs in dermatology provide enough evi-
dence in order to inform clinical decisions, a fact that is in line with
previous analyses.8,9We found that some diseases such as seborreic
dermatitis, skin manifestations of systemic disorders, and urticaria,
and some interventions such as immunizations and dietary modi-
ﬁcations, were seldom included in SRs, although the vast majority
of them are highly prevalent in dermatological practice. It is also
possible that there are more dermatological diseases not identiﬁed
in our search that had never been the subject of SRs.
Approximately one half of the analyzed SRs contained a meta-
analysis and a third of SRs were randomized controlled trial-
based, with approximately 10% of CSG-SRs. Less than 30% SRs
were performed with international collaboration. These percent-
ages are similar to those previously reported in other specialties.3,4
Surprisingly, not one CSG-SR was among the 10% most cited re-
views. This information is remarkable considering the demon-
strated fact that CSG-SRs are of higher methodological quality than
other reviews.10
Even though the number of SRs in dermatology is growing at a
steady rate, reﬂecting a general increase in published SRs,3,4 all the
aforementioned features showed to be constant within the 5 years
analyzed.Although our objective was not to develop an SR, a limitation of
this study is that some SRs could not be found, mainly because the
search was limited to three databases and to SRs with the words
“systematic review” or “meta-analysis” in the title, according to the
PRISMA statement. This could also cause bias by selecting far higher
quality reviews.
There are some other features that we did not analyze, some of
which would be interesting to assess, such as the methodological
quality of the SRs, design of included studies, and the relationship
of these to the citation count and the impact factor of the journals
where these SRs are published.
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